Article ; Online: Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice.
2008 Volume 22, Issue 7, Page(s) 2416–2426
Abstract: Recent data suggest that the gut microbiota plays a significant role in fat accumulation. However, it is not clear whether gut microbiota is involved in the pathophysiology of type 2 diabetes. To assess this issue, we modulated gut microbiota via ... ...
Abstract | Recent data suggest that the gut microbiota plays a significant role in fat accumulation. However, it is not clear whether gut microbiota is involved in the pathophysiology of type 2 diabetes. To assess this issue, we modulated gut microbiota via antibiotics administration in two different mouse models with insulin resistance. Results from dose-determination studies showed that a combination of norfloxacin and ampicillin, at a dose of 1 g/L, maximally suppressed the numbers of cecal aerobic and anaerobic bacteria in ob/ob mice. After a 2-wk intervention with the antibiotic combination, both ob/ob and diet-induced obese and insulin-resistant mice showed a significant improvement in fasting glycemia and oral glucose tolerance. The improved glycemic control was independent of food intake or adiposity because pair-fed ob/ob mice were as glucose intolerant as the control ob/ob mice. Reduced liver triglycerides and increased liver glycogen correlated with improved glucose tolerance in the treated mice. Concomitant reduction of plasma lipopolysaccharides and increase of adiponectin further supported the antidiabetic effects of the antibiotic treatment in ob/ob mice. In summary, modulation of gut microbiota ameliorated glucose tolerance of mice by altering the expression of hepatic and intestinal genes involved in inflammation and metabolism, and by changing the hormonal, inflammatory, and metabolic status of the host. |
---|---|
MeSH term(s) | Ampicillin/pharmacology ; Animals ; Anti-Bacterial Agents/pharmacology ; Bacteroides/drug effects ; Bacteroides/physiology ; Bifidobacterium/drug effects ; Bifidobacterium/physiology ; Diabetes Mellitus, Type 2/etiology ; Diabetes Mellitus, Type 2/physiopathology ; Enterobacteriaceae/drug effects ; Enterobacteriaceae/physiology ; Lactobacillus/drug effects ; Lactobacillus/physiology ; Mice ; Mice, Obese ; Microbial Sensitivity Tests ; Norfloxacin/pharmacology ; Obesity/microbiology ; Obesity/physiopathology |
Chemical Substances | Anti-Bacterial Agents ; Ampicillin (7C782967RD) ; Norfloxacin (N0F8P22L1P) |
Language | English |
Publishing date | 2008-07 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 639186-2 |
ISSN | 1530-6860 ; 0892-6638 |
ISSN (online) | 1530-6860 |
ISSN | 0892-6638 |
DOI | 10.1096/fj.07-102723 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2266: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 296: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.